Status:
UNKNOWN
Investigation of Antipsoriatic Effects of UVB-induced Synthesis of 1alpha, 25-Dihydroxyvitamin D3 (1alpha, 25(OH)2D3, Calcitriol)in Keratinocytes of Psoriatic Skin, Using Cytochrom-P(CYP)Inhibitor Ketokonazol
Lead Sponsor:
Technische Universität Dresden
Conditions:
Psoriasis Vulgaris
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
Exploration of antipsoriatic effects of UVB-therapy +/- CYP-inhibitor Ketokonazol on affected psoriatic skin
Eligibility Criteria
Inclusion
- age: 18- 80
- diagnosis of psoriasis vulgaris (mild- middle)
- no other current antipsoriatic therapy (systemic/topical)
- at least 5 psoriatic areas of 5x5 cm
Exclusion
- pregnancy/nursing mothers
- women in reproductive age without adequate contraception
- severe and acute forms of psoriasis vulgaris
- patients receiving systemic or topical antipsoroatic treatment in past 3 month
- UV-therapy in past 3 month
- patients having a positive anamnesis for squamous cell carcinoma, malignant melanoma, basalioma
- epilepsy
Key Trial Info
Start Date :
March 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2009
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00678756
Start Date
March 1 2008
End Date
December 1 2009
Last Update
June 8 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Dermatology, Medical Faculty, TU Dresden
Dresden, Germany, 01307